Vomiting clinical trials at UCSF

1 research study open to eligible people

Vomiting is the body pushing stomach contents out through the mouth. UCSF is running a study in children who receive very strong chemotherapy. The study measures vomiting episodes, nausea, and side effects.

Showing trials for

  • RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

    open to eligible people ages 30 months to 18 years

    Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy

    San Francisco, California and other locations

Our lead scientists for Vomiting research studies include .

Last updated: